Imatinib Related Compounds & Impurities

Imatinib is a BCR-ABL tyrosine kinase inhibitor that revolutionised chronic myeloid leukaemia treatment and is also used for gastrointestinal stromal tumours.

Simson Pharma Limited along with its subsidiary offices Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) is a trusted manufacturer and supplier of high-quality pharmaceutical reference standards, offering a comprehensive portfolio of Imatinib reference standards, pharmacopeial and non-pharmacopeial Imatinib impurities, related compounds, related substances, metabolites, stable isotope-labelled compounds, deuterium labelled compounds and nitrosamine (N-NO) reference standards.

These materials support pharmaceutical research and development, product development, ANDA and DMF submissions, quality control (QC), analytical method development and validation, stability studies, impurity identification, and genotoxic impurity assessment.

Our Imatinib-related reference standards are thoroughly characterized using advanced analytical techniques and are supplied with comprehensive Certificates of Analysis (COA) and supporting analytical data from our USFDA certified, ISO 17025 and ISO 17034 accredited Lab, to meet global regulatory expectations. EP and USP traceable reference standards can also be provided upon request, subject to availability. Simson is also a provider of EP and USP traceable standards. To ensure consistent quality and reliability, our reference standards are periodically re-tested according to established quality management procedures.

Pharmaceutical Reference Standards / Impurity Standards

Imatinib Mesylate
Imatinib methanesulfonate Beta form
Imatinib Mesyalte Impurity A
N-Desmethyl Imatinib Impurity
Imatinib Mesylate Impurity J
Imatinib EP Impurity F
N-DesmethylImatinib-D8
Imatinib
4-methylbenzamide
Imatinib EP Impurity F
3-[3-(Dimethylamino)acryloyl]pyridine
Imatinib Impurity ( Dimethyl amine Hydrochloride)
3-Acetylpyridine
Imatinib (Piperidine)-N,N-DiOxide
Imatinib Diamine Impurity
Imatinib impurity A
Imatinib EP Impurity B Hydrochloride
Imatinib EP Impurity D
Imatinib Carboxylic Impurity
4-((4-methylpiperazin-1-yl)methyl)benzoic acid Dihydrochloride
Imatinib Impurity 8
Imatinib Mesylate impurity 02
O-Toluidine
p-Toluic acid
2-(chloromethyl)benzoic acid
2-[(4-methylpiperazin-1-yl)methyl]Benzonitrile
3-[(4-methylpiperazin-1-yl)methyl]Benzonitrile
Imatinib Meta-Methyl-Piperazine Impurity
3-Bromomethylbenzonitrile
Imatinib (Piperidine)-N4-Oxide
Imatinib Impurity 2
3-((4-methylpiperazin-1-yl)methyl)benzoic Acid
Imatinib Impurity 3
Imatinib Impurity 5
Imatinib Impurity 6
Imatinib Impurity 1
Imatinib EP Impurity A
Imatinib (Piperidine)-N,N-DiOxide Methanesulfonate
4-(Dichloromethyl)benzonitrile
Imatinib N-Acetyl Impurity
N-Desmethyl Imatinib Mesylate
Des(methylpiperazinyl-N-methyl) Imatinib Dimer Impurity
Imatinib Dimer Impurity 1
Imatinib EP Impurity C hydrochloride
1-(2-Methyl-5-nitrophenyl)guanidine nitrate
2-Methyl-5-nitroaniline
Imatinib Nitroso Impurity 2
Imatinib EP Impurity G Diydrochloride
1-(2-Methyl-5-nitrophenyl)biguanide
N-(2-Methyl-5-nitrophenyl)-N~-Carbamoyl Guanidine
(2-Methyl-4-nitrophenyl)guanidine
1-(2-Methyl-3-nitrophenyl)guanidine
N-nitroso Imatinib
N-Desmethyl N-Nitroso Imatinib
N-Desmethyl-N-Nitroso Imatinib Impurity 1
Imatinib Mesylate Beta Form
Imatinib Hydrochloride Impurity G
Imatinib Mesylate Impurity B
(E)-3-(dimethylamino)-1-(pyridin-3-yl)prop-2-en-1-one-hydrochloride
Imatinib Mesylate Alpha Form
Imatinib (Piperidine)-N,N-DiOxide Dimethanesulfonate
Imatinib Mixture of N-oxide
4-Chloromethyl Benzoic Acid
Imatinib Impurity 9
Imatinib Impurity 23
Imatinib Impurity 4
Imatinib EP Impurity D Trifluoroacetate
Imatinib Impurity 7
Imatinib Nitroso Impurity 1
Imatinib Nitroso Impurity 3

Metabolites

Imatinib Metabolite AFN911
Imatinib Metabolite CGP71422
Imatinib Metabolite CGP72383

Isotope Labelled Compounds

Imatinib-D3
Imatinib-D8
Imatinib -D4
2-Toluidine-d7
N Desmethyl Imatinib-D4